Using Patient-friendly Composite Endpoints to Measure the Success of Acute Migraine Medications: 4th Annual Migraine Meeting, Budapest, October 2004: Proceedings

Contents......Page 4
Introduction......Page 5
Reference......Page 6
Recognition and Management of Migraine......Page 7
What Are Patients’ Expectations of Migraine Management?......Page 8
Which Treatment Outcomes Are Associated with Satisfaction?......Page 9
How Can Patients’ Expectations Be Met?......Page 11
References......Page 13
Migraine and Allodynia – the Clinical Picture......Page 14
Central Sensitisation......Page 15
Central Sensitisation and the Trigeminocervical Complex – Explaining Neck Pain......Page 16
Disinhibitory Sensitisation – Disordered Modulation of Trigeminovascular Afferent Signals......Page 18
References......Page 19
Introduction......Page 21
Clinical Trial Evidence in Favor of Early Treatment: A Critical Appraisal......Page 22
Conclusions......Page 24
References......Page 25
Introduction......Page 26
Results from Meta Analysis with Different Endpoints......Page 27
Incorporating Tolerability with Efficacy: Sustained Pain Free with No Adverse Events......Page 29
The Basis of Differences between Triptans......Page 30
References......Page 32
Introduction......Page 33
Short-Term Controlled Clinical Trials......Page 34
Long-Term Open-Label Clinical Trials......Page 35
Early Intervention post hoc Analyses......Page 36
References......Page 37
Abstract......Page 38
Randomized Controlled Trials vs. Postmarketing Surveillance Studies......Page 39
Randomized Controlled Trials vs. Postmarketing Surveillance Studies of Triptans......Page 40
Spanish and German Postmarketing Surveillance Studies......Page 41
Conclusion......Page 43
References......Page 44
Introduction......Page 45
Study Design......Page 46
Patients......Page 47
Secondary Efficacy Endpoints......Page 48
Safety and Tolerability......Page 49
Discussion......Page 50
Acknowledgments......Page 51
References......Page 52